The impact and management of acquired platelet dysfunction

Hamostaseologie

Volumn 31, Issue 1, 2011, Pages 28-40

  Scharf, Rüdiger E ^a   Rahman, M M ^a,b   Seidel, H ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b DHAKA MEDICAL COLLEGE HOSPITAL   (Bangladesh)

Author keywords

Acquired platelet dysfunction; Antiplatelet agents; Bleeding; Haemotherapy; Platelet hyperaggregability; Prothrombotic states

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIBIOTIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; DESMOPRESSIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SEROTONIN UPTAKE INHIBITOR; TIROFIBAN; TRANEXAMIC ACID;

BLEEDING; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; LABORATORY TEST; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOSIS;

BLOOD PLATELET DISORDERS; HUMANS;

EID: 79952541090     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1145     Document Type: Review

References (80)

1. Fuster V, Badimon L, Badimon JJ, Chesbro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250.
2. Ruggeri ZM. Platelet interactions with vessel wall components during thrombogenesis. Blood Cell Mol Dis 2006; 47: 1903-1910.
3. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-1685. (Pubitemid 46987859)
4. Iannacone M, Sitia G, Isogawa M et al. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 2008; 105: 629-634. (Pubitemid 351171759)
5. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscl Thromb Vasc Biol 2003; 23: 2131-2137. (Pubitemid 37532311)
6. Boucharaba A, Serre CM, Grès S et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-1725. (Pubitemid 40385527)
7. Gupta GP, Massagué J. Platelets and metastasis: a novel fatty link. J Clin Invest 2004; 114: 1691-1693.
8. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009; 116: 58-83.
9. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; 4: CD001925.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
11. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R et al. Asprin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849-1860.
12. Scharf RE. Management of bleeding in patients using antithrombotic agents: Prediction, prevention, protection and problem-oriented intervention. Hämostaseologie 2009; 29: 388-398.
13. Eikelboom, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost 2007; 5 (Suppl 1): 255-263.
14. May AE, Geisler T, Gawaz MP. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.
15. Scharf RE. Acquired platelet function defects: an underestimated but frequent cause of bleeding complications in clinical practice. In: Scharf RE (ed). Progress and Challenges in Transfusion Medicine, Hemostasis, and Hemotherapy. Freiburg: Karger 2008: 296-316.
16. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989. (Pubitemid 16028578)
17. Scharf RE. Thrombozyten und Mikrozirkulationsstörungen. Stuttgart, New York, Schattauer, 1986.
18. Scharf RE, Tomer A, Marzec UM et al. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb Vasc Biol 1992; 12: 1475-1487.
19. Hannington E, Jones RJ, Amess JAL, Wachowicz B. Migraine: a platelet disorder. Lancet 1981; 2: 720.
20. Davies JA, McNicol GP. Detection of a prethrombotic state. In: Bloom AL, Thomas DP (eds). Haemostasis and Thrombosis. Edinburgh, London, Churchill Livingstone, 1981, pp 593-609.
21. Yee DL, Sun CW, Bergeron AL et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 2723-2729. (Pubitemid 41510746)
22. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554. (Pubitemid 20176694)
23. Mammen EF. Sticky platelet syndrom. Semin Thromb Hemost 1999; 25: 361-365.
24. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386-1404.
25. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine 33/proline 33 amino acid polymorphism in membrane GPIIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-1781. (Pubitemid 19124140)
26. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet alpha2 beta1 density is associated with two silent polymorphisms in the alpha 2 coding sequence. Blood 1997; 89: 1939-1943. (Pubitemid 27132108)
27. Kritzik M, Savage B, Nugent DJ et al. Nucleotide polymorphisms in the alpha 2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998; 92: 2382-2388. (Pubitemid 28452981)
28. Weiss EJ, Bray PF, Tayback M et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-1094. (Pubitemid 26120186)
29. Ridker PM, Hennekens CH, Schmitz C et al. Pl A1/A2 polymorphism of platelet glycoprotein IIIa and the risks of myocardial infarction, stroke,, and venous thrombosis. Lancet 1997; 349: 385-388. (Pubitemid 27077666)
30. Zotz RB, Scharf RE. Platelet receptor polymorphisms and their role in cardiovascular disease. J Lab Med 2002; 26: 584-593. (Pubitemid 36033751)
31. Scharf RE, Zotz RB. Blood platelets and myocardial infarction: do hyperactive platelets really exist? Transfus Med Hemother 2006; 33: 189-199.
32. Moshfegh F, Wuillemin WA, Redondo M et al. Association of two silent polymorphisms of platelet glycoprotein Ia-IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-354. (Pubitemid 29088161)
33. Santoso S, Kunicki TJ, Kroll H et al. Associations of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-2453. (Pubitemid 29181174)
34. A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998; 79: 731-735.
35. Zotz RB, Klein M, Dauben HP et al. Prospective analysis of patients after coronary-artery bypass grafting: Platelet GPIIIa polymorphism (HPA-1/PlA2) is an inherited risk factor for bypass occlusion, myocardial infarction, and death. Thromb Haemost 2000; 81: 404-407. (Pubitemid 30148352)
36. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000; 7: 284-289. (Pubitemid 30637667)
37. 2807TT) with premature myocardial infarction. J Thromb Haemost 2005; 3: 1522-1529.
38. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297. (Pubitemid 26040846)
39. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific syergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666. (Pubitemid 28427584)
40. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-1342.
41. Antman EM, Anbe DT, Armstrong PW et al. ACC/ AHA Guidelines update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: E1-E211.
42. Braunwald E, Antman E, Beasley J et al. ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002. Circulation 2002; 106: 1893-1900.
43. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49: 2145-2150. (Pubitemid 46824115)
44. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric,, and abdominal aortic). Circulation 2006; 113: e463-e654.
45. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Circulation 2006; 113: e409-e449.
46. Fuster V, Ryden LE, Cannon DS et al. ACC/AHA/ ESC 2006 Guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114: c257-c354.
47. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-1621.
48. Sabatine MS, Cannon CP, Gibson CM et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. (Pubitemid 40397259)
49. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
50. Ahrens I, Schwarz M, Peter K, Bode C. Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers. Transf Med Hemother 2007; 34: 44-54. (Pubitemid 46173546)
51. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15-28. (Pubitemid 37361621)
52. Coller BS. Anti-GPIIb-IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-443. (Pubitemid 32663972)
53. Koscielny J, Ziemer S, Radtke H et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb 2004; 10: 195-204. (Pubitemid 38982043)
54. Wisloff, Godall HC. Prolonged bleeding time with adequate platelet count in hospital patients. Scand J Haematol 1981; 27: 45-50.
55. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20. (Pubitemid 20049639)
56. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 3547-3552.
57. Scharf RE. In vitro thromboxane synthesis of depleted platelets following renal transplantation. Thromb Haemost 1990; 64: 161-164.
58. Scharf RE, Hoffmann T, Kirchhoff EM, Kelm M. Unpublished observations. 2010.
59. Sugidachi A, Ogawa T, Kurihara A et al. The grater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5: 1545-1551. (Pubitemid 46965386)
60. 12 blockers. J Thromb Haemost 2009; 7 (Suppl 1): 262-265.
61. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI-38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
62. Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
63. Bhatt DL, Lincoff AM, Gibson M et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
64. Kastrati A, Ndrepepa G. Cangrelor - a champion lost in translation? N Engl J Med 2009; 361: 2382-2384.
65. Wallentin L, Becker RC, Budaj A et al. PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
66. Schömig A. Ticagrelor - is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009; 361: 1108-1111.
67. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.
68. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
69. Patrono C, Coller BS, FitzGerald GA et al. Plateletactive drugs: the relationship among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
70. Scharf RE. Congenital and acquired platelet function disorders. Hämostaseologie 2003; 23: 170-180. (Pubitemid 37484267)
71. Bhatt DL. Intensifying platelet inhibition - navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078-2081. (Pubitemid 350106717)
72. Serebruany VL, Malin AI, Ferguson JJ et al. Bleeding risks of combination versus single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008; 22: 315-321. (Pubitemid 351712893)
73. Ridker PM, Cook NR, Lee I-M et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
74. Rothwell PM. External validity of randomized controlled trials: 'to whom do the results of this trial apply?' Lancet 2005; 365:82-93.
75. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 257S-298S.
76. Levi M. Epidemiology and management of bleeding in patients using vitamin K antagonists. J Thromb Haemost 2009; 7 (Suppl 1): 103-106.
77. Greaves M, Watson HG. Approach to the diagnosis and management of mild bleeding disorders. J Thromb Haemost 2007; 5 (Suppl 1): 167-174. (Pubitemid 46958830)
78. Zotz RB, Scharf RE. Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia. Hämostaseologie 2007; 27: 251-262. (Pubitemid 47612020)
79. Mangano DT, Miao, Vuylsteke A et al. Mortality associated with aprotinin during five years following coronary artery bypass graft surgery. JAMA 2007; 297: 527-529.
80. Mannuci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521.